BioChek B.V., headquartered in the Netherlands, is a leading player in the veterinary diagnostics industry, specialising in innovative solutions for animal health. Founded in 1997, the company has established a strong presence in Europe and beyond, focusing on the development of advanced diagnostic tests for infectious diseases in livestock and poultry. With a commitment to quality and accuracy, BioChek offers a range of unique products, including ELISA tests and molecular diagnostics, designed to enhance disease management and biosecurity in animal production. The company’s dedication to research and development has positioned it as a trusted partner for veterinarians and farmers alike, contributing to improved animal welfare and productivity. BioChek's notable achievements include numerous certifications and a growing portfolio of international clients, solidifying its reputation as a pioneer in veterinary diagnostics.
How does BioChek B.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
BioChek B.V.'s score of 23 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
BioChek B.V., headquartered in the Netherlands, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that BioChek B.V. may still be in the early stages of developing its climate commitments or reporting framework. As the company operates within an industry increasingly focused on sustainability, it is essential for BioChek B.V. to establish clear climate goals and emissions reporting to align with global standards and expectations. Engaging in initiatives such as the Science Based Targets initiative (SBTi) or committing to carbon neutrality could enhance their environmental credibility and contribute positively to their operational sustainability.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
BioChek B.V. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
